Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor regulatory T cell infusion + rapamycin + low-dose IL-2
- Development stage
- Unknown
- Lead developer
- University of Liege
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This therapeutic approach, developed by the University of Liege, involves the infusion of donor-derived regulatory T cells (Tregs) for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). The protocol utilizes CD4+CD25+CD127low Tregs isolated from the original stem cell donor, which are infused into the patient to restore immune tolerance and suppress the inflammatory processes driving cGVHD. To support the survival, stability, and in vivo expansion of these infused cells, the therapy is combined with rapamycin (sirolimus), an mTOR inhibitor that selectively promotes Treg survival over effector T cells, and low-dose interleukin-2 (IL-2), which provides essential growth signals through the high-affinity IL-2 receptor (CD25) constitutively expressed on Tregs. This combination strategy aims to achieve long-term immune homeostasis in patients who have failed standard corticosteroid therapy.
- Other names
- Donor Treg infusionTreg-Liege protocolDonor regulatory T cell infusion
02
Targets
IL2RB (IL-2 receptor beta chain)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on donor regulatory T cell infusion + rapamycin + low-dose IL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor regulatory T cell infusion + rapamycin + low-dose IL-2.